Australia markets close in 51 minutes
  • ALL ORDS

    7,385.70
    +82.40 (+1.13%)
     
  • ASX 200

    7,139.60
    +75.10 (+1.06%)
     
  • AUD/USD

    0.7038
    -0.0011 (-0.15%)
     
  • OIL

    110.85
    -1.36 (-1.21%)
     
  • GOLD

    1,840.50
    -0.70 (-0.04%)
     
  • BTC-AUD

    42,698.41
    +1,009.50 (+2.42%)
     
  • CMC Crypto 200

    669.56
    +17.33 (+2.66%)
     
  • AUD/EUR

    0.6650
    -0.0007 (-0.11%)
     
  • AUD/NZD

    1.1008
    -0.0030 (-0.27%)
     
  • NZX 50

    11,267.39
    +60.46 (+0.54%)
     
  • NASDAQ

    11,875.63
    -52.69 (-0.44%)
     
  • FTSE

    7,302.74
    -135.35 (-1.82%)
     
  • Dow Jones

    31,253.13
    -236.94 (-0.75%)
     
  • DAX

    13,882.30
    -125.46 (-0.90%)
     
  • Hang Seng

    20,530.35
    +409.67 (+2.04%)
     
  • NIKKEI 225

    26,744.93
    +342.09 (+1.30%)
     

Why Longeveron Stock Skyrockted 661.2% in November

·2-min read
Why Longeveron Stock Skyrockted 661.2% in November
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Longeveron (NASDAQ: LGVN) jumped 661.2% in November, according to data from S&P Global Market Intelligence. The stock surged after it was announced that the company received a Rare Pediatric Disease (RPD) designation for its Lomecel-B treatment. Longeveron announced on Nov. 18 that Lomecel-B had received RPD designation for the treatment of hypoplastic left heart syndrome (HLHS) -- a potentially fatally heart condition in infants.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting